Early Effects of Sacubitril/Valsartan on Exercise Tolerance in Patients with Heart Failure with Reduced Ejection Fraction

Journal of Clinical Medicine
Giuseppe VitaleFilippo Maria Sarullo

Abstract

Sacubitril/valsartan in heart failure (HF) with reduced ejection fraction (HFrEF) was shown to be superior to enalapril in reducing the risk of death and hospitalization for HF. Our aim was to evaluate the cardiopulmonary effects of sacubitril/valsartan in patients with HFrEF. We conducted an observational study. Ninety-nine ambulatory patients with HFrEF underwent serial cardiopulmonary exercise tests (CPET) after initiation of sacubitril/valsartan in addition to recommended therapy. At baseline, 37% of patients had New York Heart Association (NYHA) class III. After a median follow-up of 6.2 months (range 3⁻14.9 months) systolic blood pressure decreased from 117 ± 14 to 101 ± 12 mmHg (p < 0.0001), left ventricular ejection fraction (LVEF) increased from 27 ± 6 to 29.7 ± 7% (p < 0.0001), peak oxygen consumption (VO₂) improved from 14.6 ± 3.3 (% of predicted = 53.8 ± 14.1) to 17.2 ± 4.7 mL/kg/min (% of predicted = 64.7 ± 17.8) (p < 0.0001), minute ventilation/carbon dioxide production relationship (VE/VCO₂ Slope) decreased from 34.1 ± 6.3 to 31.7 ± 6.1 (p = 0.006), VO₂ at anaerobic threshold increased from 11.3 ± 2.6 to 12.6 ± 3.5 mL/kg/min (p = 0.007), oxygen pulse increased from 11.5 ± 3.0 to 13.4 ± 4.3 mL/kg/min (p < 0.0001),...Continue Reading

References

May 1, 1997·The American Journal of Cardiology·G A MacGowanS Murali
Feb 5, 2004·American Heart Journal·Ross ArenaMary Ann Peberdy
Jul 27, 2010·The Open Cardiovascular Medicine Journal·Filippo Maria SarulloPietro Di Pasquale
Sep 2, 2014·The New England Journal of Medicine·John J V McMurrayUNKNOWN PARADIGM-HF Investigators and Committees
Jun 23, 2015·Current Problems in Cardiology·Jonathan MyersMarco Guazzi
Jun 11, 2016·European Journal of Heart Failure·Orly VardenyUNKNOWN Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF
Aug 6, 2016·Journal of the American College of Cardiology·Antoni Bayes-GenisA Mark Richards
Mar 23, 2017·European Journal of Heart Failure·Emilia D'EliaMichele Senni
Apr 5, 2017·Annals of the American Thoracic Society·Mauro Contini
Dec 19, 2017·International Journal of Cardiology·Paola BeltránJulio Núñez
Dec 21, 2017·Cardiology·Luca SgorbiniAlfonso Galati
Jul 25, 2018·ESC Heart Failure·Raquel Rodil FraileGregorio Tiberio López

❮ Previous
Next ❯

Citations

Dec 10, 2019·Journal of Cardiovascular Pharmacology·Marco Giuseppe Del BuonoAntonio Abbate
Feb 20, 2020·ESC Heart Failure·Francesco CacciatorePasquale Abete
Jun 14, 2020·Journal of Clinical Medicine·Venturini EGiallauria F
Aug 3, 2020·Journal of Cardiovascular Medicine·Massimo MapelliPiergiuseppe Agostoni
Aug 20, 2019·ESC Heart Failure·Raquel Rodil FraileGregorio Tiberio López
May 1, 2020·Journal of Clinical Medicine·Anna Di LorenzoFrancesco Giallauria
Jun 11, 2020·Cardiovascular Drugs and Therapy·George Chalikias, Dimitrios Tziakas
Oct 9, 2020·Journal of Cardiovascular Pharmacology·Jingwen HuQijun Shan
Oct 22, 2020·Arquivos brasileiros de cardiologia·António Valentim GonçalvesRui Cruz Ferreira
Feb 5, 2021·European Respiratory Review : an Official Journal of the European Respiratory Society·Piergiuseppe AgostoniElisabetta Salvioni
Nov 2, 2021·High Blood Pressure & Cardiovascular Prevention : the Official Journal of the Italian Society of Hypertension·Francesco GiallauriaCarmine Morisco

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT03190304

Software Mentioned

SAS JMP

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.